[go: up one dir, main page]

DK3365321T3 - Solabegron-zwitterion og anvendelser deraf - Google Patents

Solabegron-zwitterion og anvendelser deraf Download PDF

Info

Publication number
DK3365321T3
DK3365321T3 DK16858451.4T DK16858451T DK3365321T3 DK 3365321 T3 DK3365321 T3 DK 3365321T3 DK 16858451 T DK16858451 T DK 16858451T DK 3365321 T3 DK3365321 T3 DK 3365321T3
Authority
DK
Denmark
Prior art keywords
solabegron
zwitterion
Prior art date
Application number
DK16858451.4T
Other languages
English (en)
Inventor
Raymond E Stevens
Dalian Zhao
Bingidimi Itute Mobele
Original Assignee
B3Ar Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B3Ar Therapeutics Inc filed Critical B3Ar Therapeutics Inc
Application granted granted Critical
Publication of DK3365321T3 publication Critical patent/DK3365321T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/16Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26Radicals substituted by carbon atoms having three bonds to hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK16858451.4T 2015-10-23 2016-10-24 Solabegron-zwitterion og anvendelser deraf DK3365321T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562245670P 2015-10-23 2015-10-23
US201562245656P 2015-10-23 2015-10-23
US201662345357P 2016-06-03 2016-06-03
US201662345574P 2016-06-03 2016-06-03
US201662345327P 2016-06-03 2016-06-03
PCT/US2016/058516 WO2017070689A2 (en) 2015-10-23 2016-10-24 Solabegron zwitterion and uses thereof

Publications (1)

Publication Number Publication Date
DK3365321T3 true DK3365321T3 (da) 2024-01-15

Family

ID=58557973

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16858451.4T DK3365321T3 (da) 2015-10-23 2016-10-24 Solabegron-zwitterion og anvendelser deraf

Country Status (11)

Country Link
US (5) US10065922B2 (da)
EP (1) EP3365321B1 (da)
CN (2) CN114230477A (da)
CA (1) CA3001850A1 (da)
DK (1) DK3365321T3 (da)
ES (1) ES2967863T3 (da)
FI (1) FI3365321T3 (da)
IL (2) IL310527A (da)
PL (1) PL3365321T3 (da)
PT (1) PT3365321T (da)
WO (1) WO2017070689A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
EP3365321B1 (en) 2015-10-23 2023-12-13 B3AR Therapeutics, Inc. Solabegron zwitterion and uses thereof
US10298650B2 (en) * 2016-04-20 2019-05-21 Vasona Networks, Inc. Maximum sustainable encoding bit rates for video downloads
EP3634420A1 (en) 2017-06-06 2020-04-15 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
CN113164486A (zh) 2018-12-05 2021-07-23 尤偌万科学有限公司 用于治疗膀胱过度活动症症状的维贝格龙
CN111925294A (zh) * 2020-07-06 2020-11-13 济南大学 一种托特罗定帕莫酸盐及其制备方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (da) 1960-07-26
EP0006735B1 (en) 1978-06-28 1983-06-15 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
GB8519154D0 (en) 1985-07-30 1985-09-04 Ici Plc Aromatic ethers
DE3934436A1 (de) 1989-06-01 1991-04-18 Thomae Gmbh Dr K 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5061727A (en) 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
NO179246C (no) 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
WO1995033724A1 (en) 1994-06-09 1995-12-14 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
ATE239694T1 (de) 1995-10-26 2003-05-15 Mitsubishi Pharma Corp Phenylethanolamin-verbindungen und ihre anwendung als beta3 agonisten, verfahren zu ihrer herstellung und zwischenprodukte ihrer herstellung
US6123961A (en) 1996-09-25 2000-09-26 Bridge Pharma, Inc. Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
GB9812709D0 (en) * 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
US20060240105A1 (en) 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
CA2348871C (en) 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
DE19856167C1 (de) 1998-12-05 2000-05-04 Vetter & Co Apotheker Nadelschutzanordnung für Spritzen, Karpulen und dergleichen Injektionsinstrumente
GB9929297D0 (en) 1999-12-11 2000-02-02 Glaxo Group Ltd Process
EP1258253A1 (en) 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6395762B1 (en) 2000-07-17 2002-05-28 American Home Products Corporation Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US7709677B2 (en) 2001-01-31 2010-05-04 Glaxosmithkline Llc Process of preparing arylethanoldiamines
US7034053B2 (en) 2001-01-31 2006-04-25 Smithkline Beecham Corporation Phenethanolamine derivatives, compositions, and their use as agonists at atypical beta-adrenoreceptors
GB0102407D0 (en) * 2001-01-31 2001-03-14 Glaxo Group Ltd Process
AU2002252364B2 (en) 2001-03-13 2005-08-25 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
WO2003024483A1 (fr) 2001-09-11 2003-03-27 Fujisawa Pharmaceutical Co., Ltd. Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire
TW200800953A (en) 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
EP1424079A1 (en) 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
AU2004285289A1 (en) 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor
DE10352132A1 (de) 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
PL1694354T3 (pl) 2003-11-27 2009-12-31 Develogen Ag Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
CA2551167C (en) * 2003-12-23 2011-10-18 Astellas Pharma Inc. Aminoalcohol derivatives
CA2552064A1 (en) 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
EP1550447A1 (en) 2004-01-02 2005-07-06 Schering Aktiengesellschaft Menstrual cycle control and improvement of conception rates in females
WO2005077364A1 (ja) 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
EP1804778A1 (de) 2004-10-18 2007-07-11 Boehringer Ingelheim International GmbH Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts
AU2006236423B2 (en) 2005-04-19 2009-12-10 Novartis Ag Pharmaceutical composition
EP1769792A1 (de) 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
ITMI20061581A1 (it) 2006-08-04 2008-02-05 Univ Bari Ligandi del recettore beta-3 adrenergico e loro uso in terapia
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
CA2681749A1 (en) 2007-03-29 2008-10-09 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
WO2008122014A1 (en) 2007-04-02 2008-10-09 Theracos, Inc. Benzylic glycoside derivatives and methods of use
GB0714790D0 (en) 2007-07-30 2007-09-12 Jagotec Ag Improvements in or relating to organic compounds
DK2216021T3 (da) 2007-11-02 2012-11-05 Astellas Pharma Inc Farmaceutisk sammensætning til behandling af overaktiv blære
JP2011516482A (ja) 2008-04-04 2011-05-26 メルク・シャープ・エンド・ドーム・コーポレイション β3アドレナリン作動性受容体アゴニストとしてのヒドロキシメチルピロリジン
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
EP2181707A1 (en) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
WO2010118291A2 (en) 2009-04-10 2010-10-14 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
EP2427194B1 (en) 2009-05-08 2014-10-08 Merck Sharp & Dohme Corp. Pyrrolidine-derived beta 3 adrenergic receptor agonists
WO2010147830A2 (en) 2009-06-15 2010-12-23 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
EP2470021B1 (en) 2009-08-27 2014-10-22 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
BR112012004333A2 (pt) 2009-08-27 2015-09-08 Merck Sharp & Dohme composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BR112012007829A2 (pt) 2009-10-07 2015-09-22 Merck Sharp & Dohme método para tratar bexiga hiperativa, e, composição farmacêutica.
EP2512475A1 (en) 2009-12-15 2012-10-24 Metabolic Solutions Development Company LLC Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases
WO2011075514A1 (en) 2009-12-15 2011-06-23 Metabolic Solutions Development Company Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
CN102753170A (zh) 2009-12-15 2012-10-24 新陈代谢解决方案开发公司 治疗糖尿病及其它代谢性疾病的ppar节制的噻唑烷二酮和组合
JP5812500B2 (ja) 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 新規なβ3アドレナリン作動性受容体アゴニスト
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) * 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
AP2013006742A0 (en) 2010-08-03 2013-02-28 Altherx Inc Combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonsits for treatment of overactive bladder
WO2016004056A1 (en) 2014-07-03 2016-01-07 Velicept Therapeutics, Inc. Pharmaceutical combinations
WO2012154770A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
AR089957A1 (es) 2012-02-09 2014-10-01 Altherx Inc Combinaciones farmaceuticas, combinaciones sinergicas
ES2394349B1 (es) 2012-08-29 2013-11-04 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
SG11201501415RA (en) 2012-08-31 2015-05-28 Astellas Pharma Inc Orally administered medical composition
US20150306170A1 (en) 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release
US20150158809A9 (en) * 2013-02-26 2015-06-11 Xenoport, Inc. Method of making 1-(acyloxy)-alkyl carbamate compounds
MX2016010213A (es) * 2014-02-07 2017-04-13 Auspex Pharmaceuticals Inc Formulaciones farmaceuticas novedosas.
US9956194B2 (en) * 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
EP3365321B1 (en) 2015-10-23 2023-12-13 B3AR Therapeutics, Inc. Solabegron zwitterion and uses thereof
US20170348263A1 (en) 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
EP3463312A4 (en) 2016-06-03 2020-02-05 Velicept Therapeutics, Inc. DOSAGE DIAGRAMS FOR BETA-3 ADRENERGIC RECEPTOR AGONISTS AND ANTI-MUSCARIN AGENTS FOR THE TREATMENT AND PREVENTION OF LOWER URINARY SYMPTOMS AND VESICAL HYPERACTIVITY
US20240197660A1 (en) 2021-03-31 2024-06-20 B3Ar Therapeutics, Inc. Compositions of micronized solabegron and methods of use

Also Published As

Publication number Publication date
EP3365321A4 (en) 2019-06-05
US20210317073A1 (en) 2021-10-14
PL3365321T3 (pl) 2024-03-25
IL310527A (en) 2024-03-01
EP3365321B1 (en) 2023-12-13
US10844004B2 (en) 2020-11-24
US20190185414A1 (en) 2019-06-20
US20240124391A1 (en) 2024-04-18
FI3365321T3 (fi) 2024-01-02
IL258856B2 (en) 2024-07-01
EP3365321A2 (en) 2018-08-29
CN108290824A (zh) 2018-07-17
US20180370902A1 (en) 2018-12-27
CN114230477A (zh) 2022-03-25
ES2967863T3 (es) 2024-05-06
CN108290824B (zh) 2022-03-11
WO2017070689A2 (en) 2017-04-27
US10221126B2 (en) 2019-03-05
IL258856A (en) 2018-06-28
IL258856B1 (en) 2024-03-01
US10065922B2 (en) 2018-09-04
PT3365321T (pt) 2024-01-12
WO2017070689A3 (en) 2017-07-20
HK1258038A1 (en) 2019-11-01
US11691944B2 (en) 2023-07-04
CA3001850A1 (en) 2017-04-27
US12435026B2 (en) 2025-10-07
US20170114005A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3368534T3 (da) Valbenazin-ditosylat og polymorfer deraf
IL280863A (en) Autotaxin inhibitors and uses thereof
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3333191T3 (da) Anti-C10ORF54-antistoffer og anvendelser deraf
DK3480213T3 (da) Syntac-polypeptider og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
DK3210977T3 (da) Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
DK3099172T3 (da) Modificeret biologisk bekæmpelsesmiddel og anvendelser deraf
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3236991T3 (da) Fgf21-derivater og anvendelser deraf
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3256598T3 (da) Svampestammer og anvendelsesfremgangsmåder
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3337506T3 (da) Kombinationer og anvendelser deraf
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
DK3245219T3 (da) Glypicanepitoper og anvendelser deraf
DK3256479T3 (da) 4-substituerede benzoxaborolforbindelser og anvendelser deraf
DK3280405T3 (da) Inhibitorer og anvendelser deraf